KLK3 and cancer: Other oncolytic Ads constructed with cancer-selective promoters, such as OBP-301 (Telomelysin) driven by human telomerase reverse transcriptase (hTERT) promoter [28] and CV706 driven by prostate-specific antigen (PSA) promoter [29], have progressed to human clinical trials.